MAP2K7 and non-small cell lung carcinoma: The addition of a MEK inhibitor to docetaxel demonstrated better outcomes in patients with KRAS-mutant NSCLC compared with either single-agent treatment, combination with erlotinib or docetaxel alone [202,203].